Akorn Company Profile (NASDAQ:AKRX)

About Akorn (NASDAQ:AKRX)

Akorn logoAkorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:AKRX
  • CUSIP: 00972810
  • Web: www.akorn.com
  • Market Cap: $4.19 billion
  • Outstanding Shares: 124,555,000
Average Prices:
  • 50 Day Moving Avg: $33.48
  • 200 Day Moving Avg: $27.81
  • 52 Week Range: $17.61 - $35.40
  • Trailing P/E Ratio: 22.94
  • Foreward P/E Ratio: 18.77
  • P/E Growth: 4.13
Sales & Book Value:
  • Annual Revenue: $1.1 billion
  • Price / Sales: 3.80
  • Book Value: $6.99 per share
  • Price / Book: 4.81
  • EBIDTA: $445.85 million
  • Net Margins: 16.64%
  • Return on Equity: 30.32%
  • Return on Assets: 12.62%
  • Debt-to-Equity Ratio: 0.93%
  • Current Ratio: 4.21%
  • Quick Ratio: 3.22%
  • Average Volume: 3.53 million shs.
  • Beta: 1.36
  • Short Ratio: 2.35

Frequently Asked Questions for Akorn (NASDAQ:AKRX)

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 EPS for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.03. The company earned $280.70 million during the quarter, compared to analysts' expectations of $272.99 million. Akorn had a return on equity of 30.32% and a net margin of 16.64%. The business's quarterly revenue was up 27.1% on a year-over-year basis. View Akorn's Earnings History.

Where is Akorn's stock going? Where will Akorn's stock price be in 2017?

14 brokerages have issued twelve-month price objectives for Akorn's shares. Their predictions range from $20.00 to $45.00. On average, they expect Akorn's share price to reach $31.20 in the next year. View Analyst Ratings for Akorn.

What are analysts saying about Akorn stock?

Here are some recent quotes from research analysts about Akorn stock:

  • 1. According to Zacks Investment Research, "Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services. " (5/8/2017)
  • 2. Royal Bank Of Canada analysts commented, "We now see two major hurdles lifted (i) a much needed reset on 2017 EPS and (ii) greater comfort on new approvals from Decatur. From here, debate will move to whether there is enough new launch revenue to offset erosion and drive growth beyond 2017. Story is de-risked meaningfully but we are still struggling to find growth off lower base. Target down to $21... Leading into 4Q we have been concerned that Street numbers for 2017 were meaningfully too high and that new approvals were not coming from the Decatur facility. First time 2017 guidance of $1.53 to $1.72 should re-set the Street's $2.17, lowering the bar for this year, and last night's announced approvals out of Decatur assuaged concerns around facility risk. In other words, two major concerns around this stock have now been removed. We have updated our model and our 2017-19E EPS move roughly $0.30 lower but still show little growth at $1.61, $1.64 and $1.69 (but we think guidance is reasonable). The re-set reduced risk but pushes valuation to 9.3x our 2018E EBITDA which is not necessarily inexpensive against the limited growth in our model." (3/2/2017)

Who are some of Akorn's key competitors?

Who are Akorn's key executives?

Akorn's management team includes the folowing people:

  • John N. Kapoor Ph.D., Chairman of the Board
  • Rajat Rai, Chief Executive Officer
  • Duane A. Portwood, Chief Financial Officer, Executive Vice President
  • Bruce Kutinsky Ph.D., Chief Operating Officer
  • Joseph P. Bonaccorsi, Executive Vice President, General Counsel, Secretary
  • Jonathon Kafer, Executive Vice President - Sales and Marketing
  • Steven Joseph Lichter, Executive Vice President - Pharmaceutical Operations
  • Randall E. Pollard, Senior Vice President, Chief Accounting Officer, Corporate Controller
  • Brian Tambi, Director
  • Kenneth S. Abramowitz, Independent Director

Who owns Akorn stock?

Akorn's stock is owned by a number of of institutional and retail investors. Top institutional investors include KAPOOR JOHN N (25.30%), Chicago Capital Management LLC (0.40%), Longfellow Investment Management Co. LLC (0.28%), Summit Creek Advisors LLC (0.19%), Havens Advisors LLC (0.14%) and Bank of Montreal Can (0.05%). Company insiders that own Akorn stock include Alan D Weinstein, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.

Who sold Akorn stock? Who is selling Akorn stock?

Akorn's stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Bank of Montreal Can, Capstone Asset Management Co. and Creative Planning. View Insider Buying and Selling for Akorn.

Who bought Akorn stock? Who is buying Akorn stock?

Akorn's stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital Management LLC, Longfellow Investment Management Co. LLC, Havens Advisors LLC, Aperio Group LLC, Oregon Public Employees Retirement Fund, LS Investment Advisors LLC, Louisiana State Employees Retirement System and State Treasurer State of Michigan. View Insider Buying and Selling for Akorn.

How do I buy Akorn stock?

Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Akorn's stock price today?

One share of Akorn stock can currently be purchased for approximately $33.60.

MarketBeat Community Rating for Akorn (NASDAQ AKRX)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  559
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Akorn (NASDAQ:AKRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 10 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $31.20 (7.14% downside)

Analysts' Ratings History for Akorn (NASDAQ:AKRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/19/2017Jefferies Group LLCReiterated RatingHold$34.00LowView Rating Details
6/27/2017Royal Bank Of CanadaSet Price TargetHold$34.00N/AView Rating Details
4/25/2017GabelliReiterated RatingBuy -> HoldHighView Rating Details
4/25/2017William BlairDowngradeOutperform -> Market PerformHighView Rating Details
4/25/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
4/25/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$29.00 -> $34.00HighView Rating Details
4/10/2017Deutsche Bank AGReiterated RatingHold$24.00LowView Rating Details
3/10/2017WallachBeth CapitalBoost Price TargetHold -> Hold$22.00 -> $25.00LowView Rating Details
12/29/2016GuggenheimReiterated RatingBuy$40.00N/AView Rating Details
12/1/2016Goldman Sachs Group, Inc. (The)Initiated CoverageSell$20.00N/AView Rating Details
11/7/2016Bank of America CorporationDowngradeBuy -> Underperform$22.00N/AView Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetBuy$45.00N/AView Rating Details
8/2/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
8/2/2016Citigroup Inc.DowngradeMarket Perform$33.80 -> $34.00N/AView Rating Details
5/26/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
3/23/2016Susquehanna Bancshares IncLower Price TargetNeutral$32.00 -> $30.00N/AView Rating Details
3/22/2016S&P Equity ResearchLower Price Target$25.98 -> $21.97N/AView Rating Details
3/21/2016NomuraLower Price TargetBuy$46.00 -> $42.00N/AView Rating Details
9/9/2015JMP SecuritiesInitiated CoverageMarket PerformN/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Akorn (NASDAQ:AKRX)
Earnings by Quarter for Akorn (NASDAQ:AKRX)
Earnings History by Quarter for Akorn (NASDAQ AKRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q4 2016$0.57$0.58$287.91 million$283.70 millionViewListenView Earnings Details
11/3/2016Q316$0.54$0.56$267.04 million$284.00 millionViewListenView Earnings Details
8/4/2016Q216$0.55$0.58$272.99 million$280.70 millionViewListenView Earnings Details
5/16/2016Q116$0.43$0.54$264.88 million$268.35 millionViewListenView Earnings Details
2/26/2015Q414$0.46$0.49$218.87 million$227.80 millionViewListenView Earnings Details
11/6/2014Q314$0.25$0.27$155.20 million$132.70 millionViewListenView Earnings Details
8/5/2014Q214$0.18$0.23$145.16 million$150.70 millionViewListenView Earnings Details
5/6/2014Q114$0.15$0.16$91.44 million$90.60 millionViewN/AView Earnings Details
3/3/2014Q413$0.14$0.14$83.37 million$85.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.13$0.14$75.06 million$77.00 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.14$0.13$74.07 million$73.90 millionViewN/AView Earnings Details
2/26/2013Q4 2012$0.12$0.13$69.42 million$71.50 millionViewN/AView Earnings Details
11/6/2012Q312$0.13$0.12$69.59 million$69.60 millionViewN/AView Earnings Details
8/7/2012$0.12$0.12ViewN/AView Earnings Details
5/8/2012$0.12$0.13ViewN/AView Earnings Details
3/6/2012$0.09$0.11ViewN/AView Earnings Details
11/1/2011$0.06$0.13ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Akorn (NASDAQ:AKRX)
Current Year EPS Consensus Estimate: $1.63 EPS
Next Year EPS Consensus Estimate: $1.79 EPS


Dividend History for Akorn (NASDAQ:AKRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Akorn (NASDAQ:AKRX)
Insider Ownership Percentage: 28.20%
Institutional Ownership Percentage: 76.09%
Insider Trades by Quarter for Akorn (NASDAQ:AKRX)
Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)
Insider Trades by Quarter for Akorn (NASDAQ:AKRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Kenneth AbramowitzDirectorSell2,691$30.44$81,914.04View SEC Filing  
6/14/2016Joseph BonaccorsiSVPSell6,500$29.84$193,960.00View SEC Filing  
6/10/2016Kenneth AbramowitzDirectorSell14,675$30.16$442,598.00View SEC Filing  
6/9/2016Bruce KutinskyCOOSell142,000$31.12$4,419,040.00View SEC Filing  
6/7/2016Ronald M JohnsonDirectorSell7,542$31.49$237,497.58View SEC Filing  
6/6/2016Kenneth AbramowitzDirectorSell10,900$31.37$341,933.00View SEC Filing  
6/3/2016Joseph BonaccorsiSVPSell90,250$31.23$2,818,507.50View SEC Filing  
6/2/2016Alan D WeinsteinDirectorSell50,000$30.93$1,546,500.00View SEC Filing  
4/21/2015Mark M SilverbergVPSell29,000$55.00$1,595,000.00View SEC Filing  
3/10/2015John N KapoorDirectorBuy19,000$44.26$840,940.00View SEC Filing  
3/3/2015Rajat RaiCEOBuy5,000$47.70$238,500.00View SEC Filing  
2/18/2015Joseph BonaccorsiInsiderSell40,827$47.33$1,932,341.91View SEC Filing  
2/10/2015Ronald M JohnsonDirectorSell17,173$46.44$797,514.12View SEC Filing  
1/26/2015Rajat RaiCEOSell873,985$41.89$36,611,231.65View SEC Filing  
1/12/2015Mark M SilverbergVPSell38,602$41.00$1,582,682.00View SEC Filing  
1/9/2015Ronald M JohnsonDirectorSell17,173$40.46$694,819.58View SEC Filing  
1/2/2015Ronald M JohnsonDirectorSell14,300$36.12$516,516.00View SEC Filing  
1/2/2015Timothy A DickCFOSell30,150$36.03$1,086,304.50View SEC Filing  
12/15/2014Brian TambiDirectorSell1,200$41.86$50,232.00View SEC Filing  
12/12/2014Adrienne L GravesDirectorSell9,557$41.09$392,697.13View SEC Filing  
12/11/2014John N KapoorDirectorSell50,000$41.19$2,059,500.00View SEC Filing  
12/9/2014John R SabatVPSell43,173$40.53$1,749,801.69View SEC Filing  
12/1/2014Timothy A DickCFOSell30,875$39.23$1,211,226.25View SEC Filing  
11/3/2014Timothy A DickCFOSell122,222$44.08$5,387,545.76View SEC Filing  
10/1/2014Timothy A DickCFOSell122,222$35.24$4,307,103.28View SEC Filing  
9/12/2014Brian TambiDirectorSell13,800$38.00$524,400.00View SEC Filing  
9/11/2014Joseph BonaccorsiInsiderSell116,800$37.89$4,425,552.00View SEC Filing  
9/8/2014Kenneth AbramowitzDirectorSell4,500$36.54$164,430.00View SEC Filing  
9/8/2014Rajat RaiCEOSell147,000$36.78$5,406,660.00View SEC Filing  
9/8/2014Timothy A DickCFOSell45,000$37.61$1,692,450.00View SEC Filing  
9/4/2014Alan D WeinsteinDirectorSell5,000$38.49$192,450.00View SEC Filing  
8/26/2014John N KapoorDirectorSell50,000$38.99$1,949,500.00View SEC Filing  
8/7/2014Rajat RaiCEOSell903,659$33.62$30,381,015.58View SEC Filing  
6/13/2014Brian TambiDirectorBuy1,000$27.62$27,620.00View SEC Filing  
5/16/2014Rajat RaiCEOBuy5,000$26.76$133,800.00View SEC Filing  
5/14/2014Kenneth AbramowitzDirectorSell2,557$26.79$68,502.03View SEC Filing  
12/9/2013Alan WeinsteinDirectorSell20,000$25.52$510,400.00View SEC Filing  
12/3/2013Kenneth AbramowitzDirectorSell5,000$25.35$126,750.00View SEC Filing  
12/12/2012Alan D WeinsteinDirectorBuy30,500$13.67$416,935.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Akorn (NASDAQ:AKRX)
Latest Headlines for Akorn (NASDAQ:AKRX)
streetinsider.com logoAkorn (AKRX) Shareholders Approve Merger With Fresenius Kabi - StreetInsider.com
www.streetinsider.com - July 19 at 9:58 PM
finance.yahoo.com logoAkorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi
finance.yahoo.com - July 19 at 4:56 PM
americanbankingnews.com logoAkorn, Inc. (NASDAQ:AKRX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 18 at 12:48 AM
finance.yahoo.com logoETFs with exposure to Akorn, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:26 PM
seekingalpha.com logoTaro Pharmaceutical: A Gem In Trouble
seekingalpha.com - July 10 at 3:39 PM
prnewswire.com logoJohnson & Weaver, Announces Investigations of Omega Protein Corporation, Monogram Residential Trust, Inc. and ... - PR Newswire (press release)
www.prnewswire.com - July 8 at 3:23 PM
finance.yahoo.com logoJohnson & Weaver, Announces Investigations of Omega Protein Corporation, Monogram Residential Trust, Inc. and Akorn, Inc.; Investors Encouraged to Contact Firm
finance.yahoo.com - July 8 at 8:01 AM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc ... - PR Newswire (press release)
www.prnewswire.com - July 7 at 6:01 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) and Lead Plaintiff Deadline: August 21, 2017
finance.yahoo.com - July 6 at 5:02 PM
finance.yahoo.com logoETFs with exposure to Akorn, Inc. : July 3, 2017
finance.yahoo.com - July 3 at 3:37 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akorn, Inc. (AKRX)
finance.yahoo.com - June 30 at 3:44 PM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akorn, Inc. (AKRX) - PR Newswire (press release)
www.prnewswire.com - June 29 at 4:39 PM
americanbankingnews.com logoZacks: Analysts Anticipate Akorn, Inc. (AKRX) Will Post Quarterly Sales of $259.85 Million
www.americanbankingnews.com - June 29 at 12:54 PM
prnewswire.com logoGeneric Drugs Stocks on Investors' Radar -- Akorn, Collegium Pharma, Momenta Pharma, and Diplomat Pharma - PR Newswire (press release)
www.prnewswire.com - June 28 at 3:56 PM
americanbankingnews.com logoAkorn, Inc. (AKRX) Expected to Post Earnings of $0.41 Per Share
www.americanbankingnews.com - June 27 at 9:06 AM
americanbankingnews.com logoAkorn, Inc. (AKRX) Lifted to Buy at BidaskClub
www.americanbankingnews.com - June 24 at 9:06 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Akorn, Inc.
finance.yahoo.com - June 22 at 8:31 PM
americanbankingnews.com logoAkorn, Inc. (AKRX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - June 21 at 12:38 AM
finance.yahoo.com logoETFs with exposure to Akorn, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 3:31 PM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) and Akorn (AKRX) Head to Head Comparison
www.americanbankingnews.com - June 18 at 12:28 PM
finance.yahoo.com logoAkorn, Inc. :AKRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:03 PM
feeds.benzinga.com logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Akorn, Inc. (AKRX)
feeds.benzinga.com - June 2 at 8:22 PM
americanbankingnews.com logoAkorn, Inc. (AKRX) Expected to Post Quarterly Sales of $259.85 Million
www.americanbankingnews.com - June 2 at 11:16 AM
nasdaq.com logoNotable ETF Inflow Detected - PJP, AKRX, BMY, BAX - Nasdaq
www.nasdaq.com - June 1 at 3:37 PM
americanbankingnews.com logo Analysts Expect Akorn, Inc. (AKRX) to Post $0.41 Earnings Per Share
www.americanbankingnews.com - June 1 at 12:20 AM
americanbankingnews.com logoRoyal Bank of Canada Analysts Give Akorn, Inc. (AKRX) a $34.00 Price Target
www.americanbankingnews.com - May 27 at 9:34 AM
americanbankingnews.com logoAkorn, Inc. (AKRX) Short Interest Update
www.americanbankingnews.com - May 27 at 7:08 AM
americanbankingnews.com logoAkorn, Inc. (AKRX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 27 at 12:46 AM
prnewswire.com logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX - PR Newswire (press release)
www.prnewswire.com - May 23 at 3:30 PM
finance.yahoo.com logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX
finance.yahoo.com - May 23 at 3:30 PM
seekingalpha.com logoTracking John Paulson's Paulson & Company Portfolio - Q1 2017 Update
seekingalpha.com - May 21 at 6:55 AM
nasdaq.com logoREFILE-Fresenius vows to take breather after three deals
www.nasdaq.com - May 12 at 8:59 PM
finance.yahoo.com logoTop 3 Companies Owned by Valeant (VRX)
finance.yahoo.com - May 9 at 9:22 AM
americanbankingnews.com logoZacks Investment Research Upgrades Akorn, Inc. (AKRX) to "Hold"
www.americanbankingnews.com - May 8 at 11:26 PM
americanbankingnews.com logo$0.41 EPS Expected for Akorn, Inc. (AKRX) This Quarter
www.americanbankingnews.com - May 5 at 10:21 PM
investorplace.com logoAkorn, Inc. (AKRX), Seaboard Corp (SEB) Lead 10 Notable Investor Filings - Investorplace.com
investorplace.com - May 5 at 3:27 PM
investorplace.com logoAkorn, Inc. (AKRX), Seaboard Corp (SEB) Lead 10 Notable Investor Filings
investorplace.com - May 5 at 12:19 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Akorn, Inc. -AKRX - Yahoo Finance
finance.yahoo.com - May 3 at 3:30 PM
americanbankingnews.com logoAkorn (AKRX) Given Media Impact Rating of 0.11
www.americanbankingnews.com - May 3 at 10:18 AM
finance.yahoo.com logoFresenius Tops Estimates, Raises Outlook
finance.yahoo.com - May 3 at 7:57 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Akorn, Inc. -AKRX
finance.yahoo.com - May 2 at 6:52 AM
americanbankingnews.com logoAkorn, Inc. (AKRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 2 at 12:28 AM
finance.yahoo.com logoFresenius Buys Akorn -- What Now?
finance.yahoo.com - May 1 at 3:28 PM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
finance.yahoo.com - April 30 at 9:45 PM
americanbankingnews.com logoAkorn (AKRX) Earning Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 10:08 AM
finance.yahoo.com logoMerger Buzz Drives Akorn to Top of Health Chart in April
finance.yahoo.com - April 28 at 4:21 PM
americanbankingnews.com logoAkorn, Inc. (AKRX) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 28 at 7:10 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed ...
finance.yahoo.com - April 27 at 3:47 PM
americanbankingnews.com logoAkorn (AKRX) Receives News Sentiment Rating of 0.31
www.americanbankingnews.com - April 27 at 2:34 PM
finance.yahoo.com logoAKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akorn, Inc.
finance.yahoo.com - April 27 at 1:44 AM



Akorn (AKRX) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by MarketBeat.com Staff